Skip to content
Biodatica
Start free

Dragonboat Biopharmaceutical Company Limited

Shanghai, Shanghai Municipality

OncologyantibodyFiled/Approved
Compare Sign in to watch

What changed

Phase I trial registered: A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

1w agoTrial registeredJul 9, 2026Source filing (opens the source filing in a new tab)

Momentum

91no change

Momentum 91 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

67 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jun 30, 2026

    NSCLC · NOT_YET_RECRUITING · sponsor: Sichuan University · A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

    ClinicalTrials.gov · NCT07692048 (opens the source filing in a new tab)

  2. Trial

    EARLY_PHASE1 registered

    Jan 1, 2026

    B Cell Malignancies · NOT_YET_RECRUITING · sponsor: Sichuan University · Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection

    ClinicalTrials.gov · NCT07332663 (opens the source filing in a new tab)

  3. Trial

    PHASE4 registered

    Aug 1, 2025

    Breast Cancer · NOT_YET_RECRUITING · sponsor: Shandong Cancer Hospital and Institute · Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

    ClinicalTrials.gov · NCT07093931 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    May 1, 2025

    Breast Cancer · RECRUITING · sponsor: Shandong Cancer Hospital and Institute · Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

    ClinicalTrials.gov · NCT06802757 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Feb 1, 2025

    Lung Cancer, Non-Small Cell · RECRUITING · sponsor: Sichuan University · A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

    ClinicalTrials.gov · NCT06769295 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Jan 29, 2021

    Advanced Malignant Tumor · COMPLETED · sponsor: Dragonboat Biopharmaceutical Company Limited · An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

    ClinicalTrials.gov · NCT04739111 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources